Functional Fluidics’ proprietary biomarker are unique diagnostic platforms that assess red blood cell health by replicating the environment that red blood cells experience in our bodies. Our biomarker provide indices that determine health of the patient.
Functional Fluidics offers Contract Research and Send Out Testing Services across the US. Our partners include clinical providers, pharmaceutical, academic and biotech partners.
Our experienced scientific and technical team can assist in developing a successful research strategy to facilitate clinical studies/trials for our pharma partners. We can also work with Clinical Providers to determine what is the best testing process for their patients.
Our services have recently expanded to support the COVID-19 screening and testing needs within the U.S.
Functional Fluidics provides Contract Research Services to pharmaceutical, BioTech and Academic Research companies. We are well-positioned to address the needs of clients with large-scale validation studies and to provide insights into the individual patient-level response critical for development of personalized medical applications.
Our suite of proprietary cell function assays can help validate assumptions or support clinical claims. If your organization is in the Pre-Clinical, Clinical or Post-Marketing research stage, you can benefit from our biomarkers and our expertise in defining Red Blood Cell Health.
Functional Fluidics offers Send Out Testing services to Clinical Providers. The test data is then used for patient monitoring as a clinical support tool.
Healthcare providers partner with Functional Fluidics to gain access to well-validated biomarkers to objectively assess the impact on red blood cell health, and ultimately their patients’ health.
Contract Research Services leveraging our proprietary biomarker assays to support the advancement of red blood cell therapies.
LEARN MORE
Improving patient lives while reducing the inefficiencies and costs across the healthcare network.
LEARN MORE
As we continue our growth, we invite those interested in investing our expansion to engage with our team
LEARN MORE
Proprietary Lab Tests
.png?width=80&name=New%20Project(1).png)
CLIA Certified Lab
.png?width=106&name=New%20Project(5).png)
Complex Tests Experience
.png?width=106&name=New%20Project(2).png)
Thought Leader Access
.png?width=80&name=New%20Project(3).png)
Specialized Staff
.png?width=106&name=New%20Project(4).png)
Strong Industry Relationships
Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.
Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.
Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.
The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.
LEARN MORE Functional Fluidics Biomarker Featured in ELIPSIS article in American Society of Hematology (ASH) Blood Magazine
Key Points
Hemolytic Biomarkers Predict Adhesiveness of Sickle Blood Cells in a Clinical Adhesion Bioassay
The objective of this study was to identify hematologic lab values that contribute to cellular adhesion in our clinical adhesion bioassay.
Evaluation of Coagulation and Inflammatory Markers in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO)
The aims of this study were to evaluate if novel laboratory tests could better predict patients at risk for bleeding and/or thrombosis compared to routine laboratory tests
Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease
Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dosedependent manner
Impact of environment on Red Blood Cell ability to withstand mechanical stress
An approach to measuring RBC haemolysis and profiling RBC mechanical fragility
Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay
A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease
